Day: May 13, 2020

SAN DIEGO, May 13, 2020 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that three abstracts highlighting its drug candidate tipifarnib have been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) Virtual Scientific Program, to be held May 29-31, 2020.“We are pleased to announce the presentation of three clinical abstracts for tipifarnib, including an oral presentation highlighting single-agent activity in multiple solid tumors with HRAS mutations,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. “In addition, the oral presentation will feature compelling overall survival data from our RUN-HN Phase 2 trial...

OTTAWA, May 13, 2020 (GLOBE NEWSWIRE) — HEXO Corp. (“HEXO”, or the “Company”) (TSX: HEXO; NYSE: HEXO) today announced that it received notification from the New York Stock Exchange (the “NYSE”) on April 7, 2020 that the Company was no longer in compliance with the NYSE’s US$1.00 share price continued listing standard (the “Price Listing Standard”) as a result of the average closing price of its common shares on the NYSE falling below US$1.00 for a consecutive 30 trading-day period. The issuance of the notification was not discretionary and is sent automatically when a listed company’s share price falls below the Price Listing Standard.Under the NYSE’s rules, the Company can regain compliance with the Price Listing Standard and avoid delisting if, within six months from the date of the NYSE notification, its common shares have...

OTTAWA, 13 mai 2020 (GLOBE NEWSWIRE) — HEXO Corp (« HEXO », ou la « Société ») a annoncé aujourd’hui que le 7 avril 2020 la Société a reçu un avis écrit de la Bourse de New York (le « NYSE ») indiquant que la Société ne satisfaisait pas actuellement à la norme de maintien de la cotation en bourse du NYSE à 1 dollar US (la « norme de cotation ») en raison de la chute du cours de clôture moyen de ses actions ordinaires au NYSE en dessous de 1 dollar US au bout de 30 jours de négociation consécutifs. L’émission de cet avis n’était pas discrétionnaire et se fait automatiquement lorsque le prix de l’action d’une société cotée tombe en dessous de la norme de cotation.En vertu des règles du NYSE, la Société peut se conformer de nouveau à la norme de cotation des prix et éviter d’être radiée de la cote...

WESTFORD, Mass., May 13, 2020 (GLOBE NEWSWIRE) — Kadant Inc. (NYSE: KAI) announced today that its Board of Directors has authorized the repurchase of up to $20 million of its equity securities effective May 13, 2020 through May 13, 2021. Repurchases may be made in public or private transactions, including under Securities Exchange Act Rule 10b-5-1 trading plans. The timing and amount of any repurchases will be at the discretion of Company management and will be based on market conditions and other considerations, including limitations contained in our credit agreement entered into on March 1, 2017, as amended. The Company has not repurchased any shares of its common stock under the existing $20 million authorization that will expire on May 15, 2020.About KadantKadant Inc. is a global supplier of high-value, critical components and...

Maintains strong balance sheet with EUR 18.5 million (USD 20.3 million) in cash as of March 31, 2020Signs exclusive worldwide distribution agreement with Exact Imaging to combine their innovative micro-ultrasound technology with Focal One to offer an end-to-end focal therapy solution for the diagnosis and management of prostate cancerAnnounces strategic refocusing of future development programs towards high intensity focused ultrasound (HIFU) and related growth opportunitiesCompany to host a conference call tomorrow, May 14 at 8:30 am EDTLYON, France, May 13, 2020 — EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic energy based therapies, announced today financial results for the first quarter of 2020 and provided an update on strategic and operational developments. Marc Oczachowski, EDAP’s Chief Executive...

TORONTO, May 13, 2020 (GLOBE NEWSWIRE) — Capstone Infrastructure Corporation (TSX: CSE.PR.A) (the “Corporation” or “Capstone”) today reports and filed its results for the first quarter ended March 31, 2020. The Corporation’s first quarter 2020 Management’s Discussion and Analysis (“MD&A”) and unaudited interim consolidated financial statements are available at www.capstoneinfrastructure.com and on SEDAR at www.sedar.com. Capstone’s MD&A details the “Results of Operations” and provides a “Financial Position Review” for the quarter ended March 31, 2020.Dividend DeclarationsThe board of directors today declared a quarterly dividend on the Corporation’s Cumulative Five-Year Rate Reset Preferred Shares, Series A (the “Preferred Shares”) of $0.2044 per Preferred...

At the close of business on 13 May 2020, Morten Opstad, chair of the board of IDEX Biometrics ASA, held the following voting rights in IDEX, for the purpose of the extraordinary general meeting on 15 May 2020:Total 178,118,810 shares or 24.81% of the share capital and votes, consisting of the following:Proxy to represent and vote for 111,730,411 shares or 15.56% of the share capital, including shares held by Mr Opstad and close relations.Proxy with voting instructions for 66,388,399 shares or 9.25% of the share capital.For further information contact:Marianne Bøe, Investor RelationsE-mail: marianne.boe@idexbiometrics.com   Tel: + 47 918 00186Derek D’Antilio, Chief financial OfficerE-mail: derek.dantilio@idexbiometrics.com   Tel: +1 197 827 31344About IDEX BiometricsIDEX Biometrics ASA (OSE: IDEX and OTCQB: IDXAF) is a leading provider...

IMPORTANT NOTICE         By reading the following communication, you agree to be bound by the following limitations and qualifications:This communication is for informational purposes only and is not intended to and does not constitute an offer or invitation to exchange or sell or solicitation of an offer to subscribe for or buy, or an invitation to exchange, purchase or subscribe for, any securities, any part of the business or assets described herein, or any other interests or the solicitation of any vote or approval in any jurisdiction in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. This communication should not be construed in any manner as a recommendation to any reader of this document.This communication...

Strong fourth quarter and full year revenue growth and profitabilityCompany not providing guidance for fiscal 2021 at this time due to COVID-19DUBLIN, IRELAND, May 13, 2020 (GLOBE NEWSWIRE) — STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2020 fourth quarter ended March 31, 2020.  Revenue as reported for the quarter increased 7% to $823.0 million compared with $768.2 million in the fourth quarter of fiscal 2019, with growth across all segments. Constant currency organic revenue (see Non-GAAP Financial Measures) growth was 8% for the fourth quarter of fiscal 2020.“We are pleased to end fiscal 2020 with such strong performance,” said Walt Rosebrough, President and Chief Executive Officer of STERIS. “We experienced modest financial impact from a decline in procedure volumes late...